Follicular lymphoma

What changed: Follicular lymphoma

Indication page →

Every dated change on the records linked to Follicular lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval6Regulatory2Milestone10This record1

FollowWatch this record and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-08This recordFollicular lymphoma
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026MilestoneFollicular lymphoma
Tazemetostat withdrawn worldwide
Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.

2024 · 1

2024MilestoneFollicular lymphoma
Epcoritamab and zanubrutinib-obinutuzumab approved for relapsed FL
A milestone in how this cancer is treated.

2022 · 1

2022MilestoneFollicular lymphoma
First bispecific: mosunetuzumab
Off-the-shelf CD20×CD3 with ~60% CR in third line.

2021 · 1

2021MilestoneFollicular lymphoma
CAR-T enters FL
Axicabtagene (ZUMA-5) approved; tisagenlecleucel (ELARA) 2022; lisocabtagene 2024.

2018 · 1

2018MilestoneFollicular lymphoma
RELEVANCE: chemo-free R²
Lenalidomide-rituximab matches chemo-immunotherapy first line.

2017 · 1

2017MilestoneFollicular lymphoma
Obinutuzumab first line (GALLIUM)
A milestone in how this cancer is treated.

February 2014 · 1

2014-02-20RegulatoryIodine-131 tositumomab
Iodine-131 tositumomab: withdrawal (US/CA)
Marketing of the Bexxar therapeutic regimen formally discontinued.

August 2013 · 1

2013-08-06RegulatoryIodine-131 tositumomab
Iodine-131 tositumomab: withdrawal (US/CA)
GlaxoSmithKline announced it would discontinue manufacture and sale of the Bexxar regimen, citing declining use (about 75 US patients in 2012) and available alternative therapies.

2011 · 1

2011MilestoneRituximab
PRIMA: rituximab maintenance
Two years of maintenance doubles PFS after chemo-immunotherapy.

2009 · 1

2009ApprovalIbritumomab tiuxetan
Ibritumomab tiuxetan approved in US
Consolidation after first-line chemotherapy in previously untreated follicular NHL

2005 · 1

2005ApprovalIodine-131 tositumomab
Iodine-131 tositumomab approved in CA
Same indication as the US approval

2004 · 2

2003 · 1

2003ApprovalIodine-131 tositumomab
Iodine-131 tositumomab approved in US
CD20-positive relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin lymphoma progressing during or after rituximab therapy

2002 · 1

2002ApprovalIbritumomab tiuxetan
Ibritumomab tiuxetan approved in US
Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma

1997 · 2

1984 · 1

1984MilestoneFollicular lymphoma
t(14;18) links BCL2 to follicular lymphoma
Tsujimoto and Croce clone the breakpoint; BCL2 becomes the first anti-apoptotic oncogene.